Compare Mesoblast Limited (MESO) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Yum China Holdings Inc — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while Yum China Holdings Inc trades at $42.88 (market cap $14.11B). The key difference: Yum China Holdings Inc is far larger — about 8.1× Mesoblast Limited's market cap, and Yum China Holdings Inc pays a 2.78% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Yum China Holdings Inc for 77 Days on average.
| MESO | YUMC | |
|---|---|---|
Market Cap | $1.75B | $14.11B |
Volume | 239,027 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $57.95 |
52-Week Low | $13.19 | $39.98 |
Typical Hold Time | 15 Days | 77 Days |
Enterprise Value | $1.83B | $15.02B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
YUMC trades at $42.99, up 5.76% today, with a bearish technical signal but strong fundamentals. Recent earnings beats and a 73.68% analyst buy consensus highlight positive momentum. The company completed the Pizza Hut China brand acquisition and expanded its Burger Bar concept, signaling growth initiatives. Cash flow from operations remains robust at $1.47B for 2025, though net cash flow is negative due to financing activities.
The outlook is mixed: solid earnings growth and expansion potential support upside, but technical weakness and competitive pressures pose risks. Investors should weigh the attractive valuation (P/E 15.3) against near-term price volatility and market sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
